上海海顺新型药用包装材料股份有限公司 2023年度独立董事述职报告 （夏宽云） 各位股东、股东代表： 作为上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 第五届董事会独立董事，2023年度，本人严格按照《中华人民共和国 公司法》《中华人民共和国证券法》《深圳证券交易所上市公司自律 监管指引第2号——创业板上市公司规范运作》《公司章程》以及《公 司独立董事工作制度》等有关法律、法规、制度的规定和要求，恪尽 职守，勤勉尽责，促进公司的规范运作，维护全体股东尤其是中小股 东的利益，充分发挥独立董事的作用。现将本人2023年度担任公司独 立董事的履职情况报告如下： 一、独立董事基本情况 本人夏宽云，中国国籍，拥有希腊永久居留权，1962年3月出生， 博士研究生学历，高级会计师。历任宁波大学国际金融学院团总支书 记和会计系主任、上海贝岭股份有限公司财务部总监、上海国家会计 学院副教授、东方有线网络有限公司财务部总经理，浙江九洲药业股 份有限公司董事、财务总监。现任上海树山投资管理有限公司执行董 事，上海国家会计学院副教授、硕士研究生导师，南京诺唯赞生物科 技股份有限公司独立董事、广汇汽车服务股份有限公司独立董 ...

本次申请银行综合授信额度尚需提交公司股东大会审议。 特此公告。 上海海顺新型药用包装材料股份有限公司 | 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2024-041 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 上海海顺新型药用包装材料股份有限公司 关于申请2024年度综合授信额度的公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 | | --- | | 记载、误导性陈述或重大遗漏。 | 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2024年4月17日召开了第五届董事会第十八次会议和第五届监事会 第十六次会议，审议通过了《关于申请2024年度综合授信额度的议案》， 同意公司及子公司向银行申请不超过人民币18亿元的综合授信额度， 以满足公司日常生产经营和业务发展的资金需求，授信期限为本年度 股东大会审议批准之日起至下一年度股东大会召开之日有效。 综合授信内容包括但不限于流动资金贷款、信用证、银行承兑汇 票、保函、应收账款贸易融资、超短融票据授信、建设项目贷款、并 购贷款等业务（具体授信银行、 ...

上海海顺新型药用包装材料股份有限公司 2023 年度总经理工作报告 2023 年，公司管理层在董事会的领导下，严格按照《中华人民 共和国公司法》《中华人民共和国证券法》等法律法规和《公司章程》 等公司制度的要求，贯彻执行股东大会、董事会的各项决议，对当前 复杂的国内外经济形势和行业趋势做了科学的分析，带领公司全体员 工共同努力，积极开拓国内外市场，不断提高生产效率，在市场营销、 品牌建设、数字化转型、技术创新、品质管理、降本增效等方面取得 了进步。现由我代表公司管理层向公司董事会作 2023 年度总经理工 作报告，请各位董事予以审议： 一、2023 年度公司总体经营情况 2023年面对经济增长放缓、供给侧深化改革等严峻挑战，上海海 顺新型药用包装材料股份有限公司（以下简称"公司"）管理团队和 全体员工在董事会的带领下，持续技术创新、有效落实生产、积极开 拓市场，努力完成期初制定的各项指标任务，公司经营呈现良性发展 趋势。公司实现营业收入1,020,872,006.74元，同比增长0.82%；归 属于公司股东的净利润为85,441,741.28元，同比减少16.61%。 截至2023年12月31日，公司资产总额 ...

上海海顺新型药用包装材料股份有限公司 2023年度财务决算报告 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 依据 2023 年度经营情况和财务状况，结合公司报表数据编制了《20 23 年度财务决算报告》，现将 2023 年度财务决算的有关情况汇报如 下： 公司 2023 年度财务会计报表经天健会计师事务所（特殊有限合 伙）审计，出具了"天健审〔2024〕2-163 号"标准无保留意见的审 计报告，认为公司财务报表在所有重大方面按照企业会计准则的规定 编制，公允地反映了公司 2023 年 12 月 31 日的合并及母公司财务状 况，以及 2023 年度的合并及母公司经营成果和现金流量。 | | 2023 年 | 2022 年 | 本年比上年 | | --- | --- | --- | --- | | | | | 增减 | | 营业总收入（元） | 1,020,872,006.74 1,012,601,235.55 | | 0.82% | | 归属于上市公司股东 | 85,441,741.28 | 102,461,491.00 | -16.61% | | 的净利润（元） | | | | | 归属于上 ...

Financial Performance - The net profit attributable to shareholders increased by 16.47% to CNY 32,907,068.87 for the current period[10] - The total profit for the period was approximately ¥98 million, a slight decrease from ¥98 million in the previous period[37] - Net profit attributable to shareholders was approximately ¥75.83 million, down from ¥83.28 million year-over-year, representing a decrease of about 8.7%[37] - The total comprehensive income for the period was approximately ¥83.09 million, compared to ¥88.25 million in the previous period[37] - The company reported a tax expense of approximately ¥14.91 million, an increase from ¥9.96 million in the previous period[37] Assets and Equity - The company's total assets increased by 25.42% year-on-year, reaching CNY 2,891,422,096.04[10] - The company's equity attributable to shareholders increased by 14.08% to CNY 1,821,378,591.60[10] - The company's equity attributable to shareholders rose to ¥1,821,378,591.60 from ¥1,596,620,328.83, an increase of approximately 14.0%[35] Cash Flow - The operating cash flow net amount decreased by 92.88% to CNY 3,841,952.56 compared to the same period last year[10] - The company reported a net cash inflow from financing activities of approximately ¥588.14 million, compared to a net outflow of ¥82.21 million in the previous period[39] - Cash flow from operating activities was not detailed but is critical for assessing operational efficiency[39] - Operating cash inflow for the current period was $741,312,789.73, a decrease of 3.9% from $771,067,723.75 in the previous period[52] - Net cash flow from operating activities was $3,841,952.56, significantly down from $53,983,974.44 in the previous period[52] Investments and Financing - The company issued convertible bonds, resulting in a cash inflow from financing activities of CNY 750,016,076.36, a 595.45% increase[5] - The financial expenses increased by 197.33% to CNY 11,143,921.65, mainly due to the recognition of financing costs from the issuance of convertible bonds[5] - Cash inflow from investment activities totaled $70,232,116.84, down 68.5% from $223,437,374.11 in the previous period[52] - Cash paid for investments was $109,005,000.00, a decrease from $280,890,000.00 in the previous period[52] Revenue and Costs - Total operating revenue for the period reached ¥758,017,323.85, an increase from ¥713,996,348.75 in the previous period, representing a growth of approximately 6.1%[36] - Total operating costs amounted to ¥671,259,683.41, up from ¥621,293,298.22, indicating an increase of about 8.1%[36] - The net profit margin remained stable with operating profit at ¥98,261,941.35, slightly up from ¥98,236,546.57 in the previous period[36] Shareholder Information - The company had a total of 16,355 common shareholders at the end of the reporting period[29] - The largest shareholder, Lin Wuhui, holds 29.98% of the shares, amounting to 58,019,499 shares[29] Other Income and Expenses - Non-operating income from the disposal of non-current assets amounted to ¥36,791.07 for the current period, with a total of ¥31,618.24 from the beginning of the year to the end of the reporting period[11] - The company recognized government subsidies of ¥4,830,377.57 in the current period, totaling ¥9,467,389.23 from the beginning of the year to the end of the reporting period[11] - The fair value changes of trading financial assets and liabilities resulted in a gain of ¥152,543.60 for the current period, with a total of ¥415,755.48 year-to-date[11] - The company reported a loss of ¥110,242.51 from other operating income and expenses for the current period, with a total loss of ¥167,007.40 year-to-date[11] - The total amount of other non-recurring gains and losses was reported as ¥15,498,970.45 for the year-to-date period[14]

上海海顺新型药用包装材料股份有限公司 第五届董事会独立董事专门会议2024年第三次会议决议 一、独立董事专门会议召开情况 表决结果：同意票 3 票；反对票 0 票；弃权票 0 票。 （二）审议通过《关于续聘公司2024年度审计机构的议案》 天健会计师事务所（特殊普通合伙）执业经验丰富，具备承担公 司年度财务审计和其他审计的工作能力，在从事公司审计工作中尽职 尽责，能按照中国注册会计师审计准则的要求从事公司会计报表审计 工作，能遵守会计师事务所的职业道德规范，客观、公正的对公司会 计报表发表意见。公司本次续聘天健会计师事务所（特殊普通合伙） 为公司 2024 年度审计机构，相关决策程序符合相关法律、法规和《公 司章程》的规定，不存在损害公司及中小股东利益的情形。我们一致 同意该议案，并同意提交公司董事会会议审议。 表决结果：同意票 3 票；反对票 0 票；弃权票 0 票。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 第五届董事会独立董事专门会议 2024 年第三次会议（以下简称"独 立董事专门会议"）于 2024 年 4 月 15 日以现场会议的方式召开，本 次会议应出席独立董事 3 人，实际出席 ...

| 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2024-044 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 特此公告。 上海海顺新型药用包装材料股份有限公司 关于举办2023年度业绩说明会的公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 | | --- | | 记载、误导性陈述或重大遗漏。 | 公司定于2024年4月25日（星期四）15：00-17：00在全景网举行 2023年度业绩说明会。本次业绩说明会将会采用网络远程的方式举行， 投资者可登录"全景网投资者关系互动平台"（http://ir.p5w.net） 参与本次业绩说明会。 net/zj/,进入问题征集专题页面。公司将在2023年度业绩说明会上， 对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上说明会。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2024年4月17日在巨潮资讯网（http://www.cninfo.com.cn）披露 了2023年年度报告及年度报告摘要。为了更好地与广大投资者进行交 流，使投资 ...

Financial Performance - The company's operating revenue for 2023 was CNY 1,020,872,006.74, representing a 0.82% increase compared to CNY 1,012,601,235.55 in 2022[21]. - Net profit attributable to shareholders decreased by 16.61% to CNY 85,441,741.28 in 2023 from CNY 102,461,491.00 in 2022[21]. - The net profit after deducting non-recurring gains and losses was CNY 68,444,591.61, down 26.91% from CNY 93,649,802.79 in the previous year[21]. - The net cash flow from operating activities was CNY 100,596,592.11, a decrease of 26.55% compared to CNY 136,957,656.04 in 2022[21]. - Total assets increased by 29.55% to CNY 2,986,593,236.85 at the end of 2023, up from CNY 2,305,352,111.13 at the end of 2022[21]. - The company's net assets attributable to shareholders rose by 14.68% to CNY 1,831,064,236.93 at the end of 2023, compared to CNY 1,596,620,328.83 at the end of 2022[21]. - The basic earnings per share decreased by 16.98% to CNY 0.44 in 2023 from CNY 0.53 in 2022[21]. - The company achieved a total revenue of ¥1,020,872,006.74 in 2023, representing a year-on-year growth of 0.82%[52]. - Net profit attributable to shareholders decreased by 16.61% to ¥85,441,741.28, primarily due to increased financing costs and expanded production capacity[52]. - Revenue from new pharmaceutical packaging materials accounted for 91.79% of total revenue, with a year-on-year increase of 2.75%[57]. - Domestic sales contributed 89.06% of total revenue, with a slight increase of 0.09% compared to the previous year[57]. - The company reported a total sales volume of 33,408,530.94 kg, which is a 0.86% increase from the previous year[59]. - The company reported a total revenue of 1,007 million in the latest financial year[138]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a year-over-year growth of 20%[196]. Market and Industry Trends - The pharmaceutical packaging materials industry in China has surpassed a market size of 100 billion yuan, reflecting stable growth in market demand[32]. - The company focuses on high-barrier, low-adsorption, and anti-corrosion packaging materials, aiming to provide professional and precise packaging solutions for clients[36]. - The government has introduced a series of regulations to enhance the quality control standards for pharmaceutical packaging materials, requiring companies to meet higher quality thresholds[34]. - The introduction of smart packaging and anti-counterfeiting technologies is encouraged to promote industry innovation and upgrade[35]. - The government is guiding the pharmaceutical packaging industry towards consolidation and cluster development to increase industry concentration[35]. - The company is actively exploring packaging solutions in new consumption and new energy sectors, developing a series of innovative packaging materials[42]. - The company aims to enhance its export business, with a target of increasing export sales by 99.48% in the next fiscal year[107]. - The company plans to expand its market presence by launching new products, including advanced PVC and PVDC composite materials, targeting a 30% increase in production capacity by 2024[108]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[196]. Research and Development - The company has successfully applied for and obtained 152 patents, including 21 invention patents and 126 utility model patents, covering key areas such as basic material research and production process improvements[48]. - Research and development expenses increased by 13.17% to ¥50,351,367.93, indicating a focus on innovation and product development[66]. - The company is developing a new type of high-temperature sterilization liquid packaging composite film, which has completed preliminary feasibility studies and is currently in the small batch trial production stage[67]. - The company is also working on a new anti-counterfeiting PTP aluminum foil, which has completed feasibility studies and is in the customer feedback stage for small batch production[68]. - The company is committed to independent research and development, ensuring that new products meet stringent industry standards[69]. - The company is focusing on enhancing the performance of its packaging materials to ensure they meet various application environments[69]. - The company is committed to advancing its R&D efforts to align with international sustainability initiatives and market trends[70]. - The company plans to invest 100 million yuan in R&D for new technologies aimed at enhancing product efficiency[148]. Corporate Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operation from its controlling shareholders[131]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with governance standards[131]. - The company emphasizes transparency in information disclosure, utilizing multiple platforms to ensure equal access for all shareholders[133]. - The company has conducted online investor communication sessions on April 7, 2023, and August 29, 2023, discussing business development and strategic direction[133]. - The company has established specialized committees within the board to provide scientific and professional advice for decision-making[132]. - The company has implemented a "Quality Return Dual Improvement" action plan, although details on its execution were not disclosed[129]. - The management team includes experienced professionals with backgrounds in finance and materials, such as Lin Wuhui, who is the chairman and general manager[139]. - The management emphasized the importance of sustainability in new strategies, aiming for a 30% reduction in carbon footprint by 2025[148]. Environmental Responsibility - The company adheres to multiple environmental protection laws, including the Air Pollution Prevention Law and the Water Pollution Prevention Law, ensuring compliance in its operations[182]. - The company has implemented effective measures to prevent and control environmental risks in accordance with relevant laws and regulations[188]. - The company has invested in waste gas treatment equipment and continuous monitoring systems to ensure compliance with environmental laws[188]. - The company is committed to environmental responsibility, following strict regulations and maintaining a high standard of operational compliance[182]. - The company focuses on producing high-performance, low-carbon, and environmentally friendly packaging materials, such as recyclable composite materials[190]. - The company has committed to reducing carbon emissions by 25% by 2025 as part of its sustainability strategy[196]. Employee and Talent Management - The company has established a performance-based salary system, adjusting employee compensation annually based on company performance and individual contributions[166]. - The company has implemented a comprehensive welfare system, including social insurance and various employee benefits, to retain talent[166]. - The company emphasizes training programs for new employees and marketing personnel to enhance skills and knowledge[167]. - The total number of employees at the end of the reporting period is 896, with 24 in the parent company and 343 in major subsidiaries[164]. - The professional composition includes 555 production personnel, 98 sales personnel, 125 technical personnel, 29 financial personnel, and 89 administrative personnel[165]. - The educational background of employees shows 19 with master's degrees or above, 152 with bachelor's degrees, 186 with associate degrees, and 539 with high school or lower education[165]. Strategic Initiatives - The company plans to continue expanding its market presence and developing new products, although specific details on future strategies were not disclosed in the report[31]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for potential deals[148]. - The company aims to enhance its R&D efforts in high-barrier packaging materials, focusing on pharmaceutical, medical, new consumption, and new energy sectors, with a commitment to developing recyclable composite materials and functional polyolefin film materials[119]. - The company will deepen cooperation with upstream and downstream enterprises in the industry chain to optimize supply chain management, improve raw material supply stability, and reduce production costs[116].

关于上海海顺新型药用包装材料股份有限公司 2023 年度募集资金存放与使用情况的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为上海海顺 新型药用包装材料股份有限公司（以下简称"海顺新材"、"上市公司"或"公司"） 向特定对象发行股票与向不特定对象发行可转换公司债券的保荐机构，根据《证 券发行上市保荐业务管理办法》等有关规定，对海顺新材 2023 年度募集资金存 放与使用情况进行了核查，核查情况如下： 一、募集资金基本情况 （一）2021 年向特定对象发行股票 1、实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意上海海顺新型药用包装材料股份有 限公司向特定对象发行股票注册的批复》（证监许可〔2021〕2377 号），公司 由主承销商中信证券股份有限公司采用询价方式，向特定对象发行人民币普通股 （A 股）股票 37,181,705 股，发行价为每股人民币 16.18 元，共计募集资金 601,599,986.90 元，坐扣承销和保荐费用 3,309,433.90 元（不含税）以及税金 198,566.03 元后的募集资金为 598,091,986.97 元，已由主承销 ...

一、召开会议基本情况 1、股东大会届次：2023年年度股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法性及合规性： 关于召开2023年年度股东大会的通知 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 | | --- | | 记载、误导性陈述或重大遗漏。 | | 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2024-043 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 上海海顺新型药用包装材料股份有限公司 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2024年4月17日召开了第五届董事会第十八次会议，会议决定于 2024年5月8日（星期三）召开公司2023年年度股东大会。本次股东大 会采用现场投票、网络投票相结合的方式进行，现发布关于召开公司 2023年年度股东大会通知如下： 公司于2024年4月17日召开的第五届董事会第十八次会议，审议 通过《关于召开2023年年度股东大会的议案》。本次股东大会的召集 程序符合《公司法》《上市公司股东大会规则》等法律、规范性文件 及《公司章程》的相 ...